Clostridium difficile (C. difficile) is a type of bacterium that lives in people’s guts. When this bacterium grows in number, it can cause an infection, C. difficile infection (CDI) that can be mild, moderate or severe. Occasionally, after initial treatment with antibiotics, the infection can re-occur, and the more times the infection re-occurs, the more likely is this to happen again. When infection happens for second and subsequent times, treatment options become more limited and less effective. Symptoms of CDI include watery diarrhoea, painful stomach cramps, dehydration, loss of appetite, weight loss.
RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.
Cefiderocol is a new drug to treat severe infections, which are caused by a particular group of bacteria called gram-negative bacteria, which are increasingly resistant to many antibiotics. Infections such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patient stay in hospital …